(Q51060775)

27 March 2018

title

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. (English)

1 reference

27 March 2018

endometrial stromal sarcoma

main subject

1 reference

1 reference

X Cheng

1

1 reference

27 March 2018

G Yang

2

1 reference

27 March 2018

K M Schmeler

3

1 reference

27 March 2018

R L Coleman

4

1 reference

27 March 2018

X Tu

5

1 reference

27 March 2018

J Liu

6

1 reference

27 March 2018

J J Kavanagh

7

1 reference

27 March 2018

language of work or name

English

0 references

publication date

28 January 2011

1 reference

27 March 2018

published in

Gynecologic Oncology

1 reference

27 March 2018

volume

121

1 reference

27 March 2018

issue

2

1 reference

27 March 2018

page(s)

323-327

1 reference

27 March 2018

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Endometrial stromal sarcoma: a population-based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Low-grade endometrial stromal sarcoma: hormonal aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Systemic therapy for advanced uterine sarcoma: a systematic review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Hormonal therapy of endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Targeted therapies in adult soft tissue sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

PDGFR-alpha as a potential therapeutic target in uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

PDGF-alpha and PDGF-beta are expressed in endometrial stromal sarcoma: a potential therapeutic target for tyrosine kinase inhibitors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Expression of the epidermal growth factor system in endometrioid endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

ErbB-3 predicts survival in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

ERBB-2 gene overexpression and amplification in uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Epithelial growth factor receptor status in primary and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.12.360

10.1016/J.YGYNO.2010.12.360

7 January 2021

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018